Press Releases

Date Title and Summary Additional Formats
Toggle Summary Seattle Genetics Initiates Phase II Clinical Trial with SGN-15 in Lung Cancer
Bothell, WA – August 21, 2001 – Seattle Genetics, Inc. (Nasdaq: SGEN) announced the initiation of a phase II clinical trial for patients with non-small cell lung cancer with its product candidate, SGN-15, a monoclonal-antibody drug conjugate. The trial will evaluate SGN-15 in combination with the
View HTML
Toggle Summary Seattle Genetics Announces Business Update Meeting and Webcast
Bothell, WA — August 16, 2001 — Seattle Genetics, Inc. (Nasdaq: SGEN) company management will host a business update meeting on August 21, 2001 at approximately 3:45 p.m. Pacific Time. The session will include presentations on research, development and clinical trial activities.
View HTML
Toggle Summary Seattle Genetics Announces Relocation and Expansion of Corporate Headquarters
Bothell, WA – August 14, 2001 – Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the Company has relocated its corporate office and laboratory space to a new, significantly larger facility, located a short distance from their former site in Bothell’s Canyon Park area.
View HTML
Toggle Summary Seattle Genetics Signs Development and Manufacturing Agreement with ICOS for the Monoclonal Antibody Component of SGN-15
Bothell, WA – August 14, 2001 – Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the Company has entered into an agreement with ICOS Corporation (Nasdaq: ICOS) for the development and manufacture of the monoclonal antibody component of its lead antibody-drug conjugate SGN-15.
View HTML
Toggle Summary Seattle Genetics Reports Second Quarter 2001 Results
Bothell, WA — July 24, 2001— Seattle Genetics, Inc. (Nasdaq: SGEN) today reported results for its second quarter ended June 30, 2001. Revenues for the quarter were $35,000, compared to revenues of $36,000 in the second quarter of 2000. For the first six months of 2001, revenues were $35,000,
View HTML
Toggle Summary Seattle Genetics Licenses Monoclonal Antibodies from CLB-Research and Development
Bothell, WA – July 18, 2001 – Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the Company has entered into an agreement to license certain monoclonal antibodies that target cancer and immunological disease from CLB-Research and Development, located in the Netherlands.
View HTML
Toggle Summary Seattle Genetics Announces Date of Second Quarter Results and Conference Call
BOTHELL – July 11, 2001 --- Seattle Genetics (Nasdaq: SGEN) will release second quarter 2001 results on Tuesday, July 24, 2001, after the close of U.S. financial markets. This announcement will be available on the Seattle Genetics website at www.seattlegenetics.com.
View HTML
Toggle Summary Seattle Genetics Added to Russell 2000 and Russell 3000 Stock Indexes
Bothell, WA – July 10, 2001 – Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the Company has been added to the Russell 2000® and Russell 3000® stock indexes. These Russell Indexes, issued by the Frank Russell Company, are adjusted annually based on market capitalization as of May 31st.
View HTML
Toggle Summary Seattle Genetics Names Morris Rosenberg Vice President, Development
Company expands its product development and clinical manufacturing initiatives Bothell, WA – July 10, 2001 – Seattle Genetics, Inc. (Nasdaq: SGEN) announced today the appointment of Morris Z. Rosenberg as Vice President, Development. Dr. Rosenberg will be responsible for overseeing all aspects of
View HTML
Toggle Summary Seattle Genetics and Eos Biotechnology Collaborate To Develop Next Generation Antibody-Drug Conjugates For Cancer Therapy
Bothell, WA and South San Francisco, CA – June 5, 2001 – Seattle Genetics, Inc. (Nasdaq: SGEN) and Eos Biotechnology, Inc. announced today a collaboration to use Seattle Genetics’ toxic payload technology with Eos’ proprietary monoclonal antibodies directed against novel cancer targets derived from
View HTML